Xenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon Pharmaceuticals (Nasdaq: XENE) has announced it will report its third quarter 2024 financial results after U.S. market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato statunitense martedì 12 novembre 2024. L'azienda ospiterà una conferenza telefonica e una diretta web alle 16:30 ora orientale nello stesso giorno. Xenon è un'azienda biofarmaceutica focalizzata sulle neuroscienze che sviluppa prodotti per i canali ionici per l'epilessia e la depressione. Il loro candidato principale, azetukalner, è un apritore del canale del potassio Kv7 in sviluppo clinico avanzato per più indicazioni.
Xenon Pharmaceuticals (Nasdaq: XENE) ha anunciado que presentará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado estadounidense el martes 12 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 pm, hora del Este, el mismo día. Xenon es una empresa biofarmacéutica centrada en neurociencia que desarrolla productos de canales iónicos para la epilepsia y la depresión. Su candidato principal, azetukalner, es un abridor del canal de potasio Kv7 en desarrollo clínico avanzado para múltiples indicaciones.
제논 제약 (Nasdaq: XENE)는 2024년 3분기 재무 결과를 2024년 11월 12일 화요일 미국 시장 마감 후 발표할 것이라고 발표했다. 회사는 같은 날 오후 4시 30분 동부 표준시(EST)에 컨퍼런스 콜 및 웹캐스트를 개최할 예정이다. 제논은 간질 및 우울증을 위한 이온 채널 제품을 개발하는 신경과학 중심의 생명공학 회사이다. 그들의 주요 후보물질인 아제투칼네르는 여러 적응증에 대해 후기 단계의 임상 개발 중인 Kv7 칼륨 채널 개방제이다.
Xenon Pharmaceuticals (Nasdaq: XENE) a annoncé qu’il publiera ses résultats financiers du troisième trimestre 2024 après la fermeture du marché américain le mardi 12 novembre 2024. L’entreprise organisera un appel conférence et une webdiffusion le même jour à 16h30, heure de l’Est. Xenon est une société bio-pharmaceutique axée sur les neurosciences qui développe des produits à base de canaux ioniques pour l'épilepsie et la dépression. Leur candidat principal, azetukalner, est un ouvreur de canaux potassiques Kv7 en développement clinique avancé pour plusieurs indications.
Xenon Pharmaceuticals (Nasdaq: XENE) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach dem Handelsende in den USA am Dienstag, den 12. November 2024, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast veranstalten. Xenon ist ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, das Produkte für Ionenkanäle zur Behandlung von Epilepsie und Depression entwickelt. Ihr führender Kandidat, azetukalner, ist ein Kv7-Kaliumkanalöffner, der sich in der späten klinischen Entwicklung für mehrere Indikationen befindet.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024.
Conference Call/Webcast Information:
| Date: | Tuesday, November 12, 2024 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 7128308 |
A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (XENE) report Q3 2024 earnings?
What time is Xenon's (XENE) Q3 2024 earnings call?
What is Xenon's (XENE) main drug candidate?
What therapeutic areas does Xenon (XENE) focus on?
